metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
hepatocell cancer (HCC) hepatocell cancer (HCC)
versus nivolumab alone
	nivolumab plus ipilimumab
	NCI-2018-01106, 2022 Lancet Gastroenterol Hepatol 2022; 7:208-218-. NCT03222076	RCT	hepatocell cancer (HCC)	nivolumab plus ipilimumab	nivolumab	Patients With Resectable and Potentially Resectable	14 / 13	NA	inconclusive	no statistically significant result
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus nivolumab alone
	nivolumab plus ipilimumab
	NCI-2018-01106, 2022 Lancet Gastroenterol Hepatol 2022; 7:208-218-. NCT03222076	RCT	hepatocell cancer (HCC)	nivolumab plus ipilimumab	nivolumab	Patients With Resectable and Potentially Resectable	14 / 13	NA	inconclusive	no statistically significant result
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	durvalumab plus tremelimumab
	HIMALAYA, 2022 journal of clinical oncology January 19, 2022 Clin Cancer Res 2024; 30:269-273-. Annals of Oncology, 2024, NEJM Evid 2022;1(8 NCT03298451	RCT	mHCC - 1st line (L1)	durvalumab and tremelimumab	sorafenib	unresectable hepatocellular carcinoma who were naive to previous systemic treatment	393 / 389	low	conclusif	demonstrated 22 % decrease in deaths (OS) (PE) suggested 22 % decrease in deaths (OS) (extension)